Actuate Therapeutics announced that its drug elraglusib will be tested in the BEACON2 Phase 1/2 trial for children with relapsed or refractory neuroblastoma, a severe pediatric cancer. The trial will evaluate elraglusib combined with dinutuximab beta and chemotherapy to determine safety and dosage, potentially advancing to a larger randomized study. Early clinical data showed a complete response in a neuroblastoma patient, and the drug has FDA Rare Pediatric Disease designation, highlighting its potential to improve outcomes in this hard-to-treat cancer. BEACON2 is a major international study sponsored by Cancer Research UK, aiming to find better treatments for neuroblastoma.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
